Rubicon Founders, a healthcare investment firm focused on building and growing transformational companies, announced that it has made a majority investment in Horizon Infusions, which is Ohio’s largest network of ambulatory infusion centers. And BroadOak Capital will continue as a minority investor in Horizon Infusions.
Horizon Infusions operates 21 centers statewide, offering critical infusion therapies to patients with chronic conditions. Horizon is renowned for its commitment to delivering exceptional patient care in a convenient outpatient setting. With a track record of operational excellence, Horizon utilizes state-of-the-art facilities and a highly skilled team to provide a comprehensive range of infusion therapies.
With this deal, Rubicon continues to expand its portfolio of healthcare services businesses that prioritize expanding access to high-quality, low cost, and patient-centered care in optimal ambulatory care settings.
Guggenheim Securities served as financial advisor and Ropes & Gray served as legal counsel to Rubicon Founders. And Raymond James served as financial advisor, and Pillsbury Winthrop Shaw Pittman LLP and Bass Berry & Sims served as legal counsel to Horizon Infusions.
KEY QUOTES:
“We are thrilled to add Horizon Infusions to our portfolio and excited to partner with their talented leadership team as they continue expanding. We believe Horizon Infusions’ commitment to clinical and operational excellence will continue to support growth both within Ohio as well as in new markets.”
- Matt Kim, Partner at Rubicon
“We look forward to partnering with the team at Rubicon, whose strategic vision, entrepreneurial spirit and commitment to patient-centered care will be instrumental in accelerating our growth. This partnership will allow Horizon Infusions to remain independent, create growth opportunities for our employees, and continue our mission of providing superior care and lowering costs for our patients.”
- Tim Johnson, Chief Executive Officer of Horizon Infusions
“Ambulatory infusion centers deliver critical therapies in a setting that is increasingly preferred by patients, providers, and payors. With its strong operational foundation and market position, we believe the platform is well-positioned to continue capitalizing on the growing demand for ambulatory infusion services.”
- Asif Dhanani, Principal at Rubicon
